American Well Co. (NYSE:AMWL) Insider Sells $42,072.80 in Stock

American Well Co. (NYSE:AMWL) insider Phyllis Gotlib sold 4,781 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.80, for a total transaction of $42,072.80. Following the completion of the sale, the insider now directly owns 147,998 shares of the company’s stock, valued at $1,302,382.40. This trade represents a 3.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Phyllis Gotlib also recently made the following trade(s):

• On Monday, February 3rd, Phyllis Gotlib sold 299 shares of American Well stock. The shares were sold at an average price of $10.51, for a total value of $3,142.49.

American Well Trading Up 0.3 %

NYSE AMWL opened at $8.73 on Thursday. The stock’s 50 day moving average is $9.86 and its two-hundred day moving average is $9.34. The company has a market capitalization of $136.23 million, a price-to-earnings ratio of -0.62 and a beta of 1.18. American Well Co. has a 1-year low of $5.00 and a 1-year high of $21.60.

American Well (NYSE:AMWL) last posted its earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.04) by $0.27. American Well had a negative net margin of 81.83% and a negative return on equity of 56.73%. On average, analysts predict that American Well Co. will post -9.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMWL shares. Stifel Nicolaus raised their price objective on American Well from $9.00 to $10.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Wells Fargo & Company raised American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a report on Monday, January 13th. Truist Financial raised their target price on American Well from $10.00 to $12.00 and gave the stock a “hold” rating in a research report on Friday, February 14th. Morgan Stanley cut their price objective on American Well from $20.00 to $10.50 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of American Well in a report on Thursday, February 13th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, American Well has an average rating of “Hold” and an average price target of $11.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AMWL. BNP Paribas Financial Markets bought a new position in American Well in the 3rd quarter worth approximately $95,000. Walleye Capital LLC acquired a new position in shares of American Well in the 3rd quarter valued at $167,000. PDT Partners LLC acquired a new position in shares of American Well in the 3rd quarter valued at $107,000. HighTower Advisors LLC acquired a new position in shares of American Well in the 3rd quarter valued at $355,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in American Well in the 4th quarter worth $45,000. Institutional investors own 56.05% of the company’s stock.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.